CN110927308A - Method for determining concentration of cetirizine in blood plasma by liquid chromatography-mass spectrometry - Google Patents
Method for determining concentration of cetirizine in blood plasma by liquid chromatography-mass spectrometry Download PDFInfo
- Publication number
- CN110927308A CN110927308A CN201911082265.XA CN201911082265A CN110927308A CN 110927308 A CN110927308 A CN 110927308A CN 201911082265 A CN201911082265 A CN 201911082265A CN 110927308 A CN110927308 A CN 110927308A
- Authority
- CN
- China
- Prior art keywords
- cetirizine
- sample
- standard
- plasma
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/34—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N2030/042—Standards
- G01N2030/045—Standards internal
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
- G01N2030/062—Preparation extracting sample from raw material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
- G01N2030/8822—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/884—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample organic compounds
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
The invention discloses a method for determining the concentration of cetirizine in blood plasma by liquid chromatography-mass spectrometry, which adopts a liquid chromatography-mass spectrometry system to determine, and comprises the steps of firstly taking a sample to be detected, adding a certain amount of mixed organic solvent for extraction, pretreating, separating by a chromatographic column, and detecting by a mass spectrometer. The method is rapid, accurate, high in sensitivity and simple and convenient to operate, and provides a basis for determining the blood concentration of cetirizine; the linear range of the plasma standard curve of the method is 1-600 ng/mL, the precision RSD in batch and between batches is less than +/-15%, and the method is suitable for measuring the concentration of cetirizine in plasma.
Description
Technical Field
The invention belongs to the technical field of medicines, particularly relates to a method for determining a medicine, and particularly relates to a method for determining the concentration of cetirizine in blood plasma by liquid chromatography-mass spectrometry.
Background
The main component of cetirizine is cetirizine hydrochloride, the chemical name of which is (+/-) -2- [2- [4- [ (4-chlorphenyl) benzyl ] -1-piperazinyl ] ethoxy ] acetic acid dihydrochloride, and the structural formula of the cetirizine hydrochloride is as follows:
cetirizine hydrochloride is a new generation of high-efficiency non-sedating antihistamine and is used for treating seasonal and perennial allergic rhinitis, itching of eyes and skin and chronic idiopathic urticaria caused by histamine, and the central nervous system activity of the Cetirizine hydrochloride is lower compared with other antihistamines. At present, various cetirizine hydrochloride dosage forms are on the market in China, such as cetirizine hydrochloride dispersible tablets, cetirizine hydrochloride capsules, cetirizine hydrochloride oral liquid and other dosage forms.
At present, the speed, the precision and the sensitivity of the existing cetirizine determination method are all required to be improved.
Disclosure of Invention
The invention aims to provide a method for determining the concentration of cetirizine in blood plasma by liquid chromatography-mass spectrometry, which can improve the speed, the precision and the sensitivity of detection.
In order to realize the aim, the method for measuring the concentration of cetirizine in plasma comprises the following steps of:
(1) pretreatment of a plasma sample:
plasma with K2EDTA as anticoagulant, cetirizine-d 8 as internal standard; precisely adding 100 μ L of plasma sample into a 96-deep-well plate, adding 5 μ L of plasma sample at a volume ratio of 1: 1, adding 5 mu L of 0.2 ng/mu L internal standard cetirizine-d 8 solution after uniformly mixing, adding 500 mu L of acetonitrile into a 96 deep-well plate after uniformly mixing, carrying out vortex mixing for 1min, centrifuging for 10min at 20 ℃ at 3000rpm, taking 50 mu L of supernatant into the 96 deep-well plate filled with 500 mu L of mixed organic solvent, wherein the mixed organic solvent is water: acetonitrile: formic acid according to a volume ratio of 65: 35: 0.1, mixing the obtained mixture, uniformly mixing the mixture by vortex, centrifuging the mixture at the temperature of 20 ℃ and 3000rpm for 5min, and taking the mixture as a test sample to be detected;
(2) and (3) sample measurement:
injecting 10 mu L of test sample into a high performance liquid chromatography-tandem mass spectrometer, detecting chromatographic peaks of cetirizine and internal standard cetirizine-d 8 in the sample, and calculating the concentration of cetirizine in the plasma sample according to the chromatographic peaks;
(3) liquid chromatography determination, conditions are as follows:
a chromatographic column: agilent ZORBAX XDB-C18, 5 μm, column specification 50X 2.1 mm; temperature of the chromatographic column: 40 ℃; mobile phase A: the volume ratio of water to formic acid is 100/0.1; mobile phase B: the volume ratio of acetonitrile/formic acid is 100/0.1; washing liquid: the volume ratio of methanol to water is 50/50; the autosampler temperature was 15 ℃; gradient elution with flow rate of 0.4mL/min, sample size of 10 μ L, and analysis time of 3.5 min;
(4) mass spectrometry under the conditions:
the ion source is an electrospray ion source, the spraying voltage is 5000V, the atomizing temperature is 500 ℃, the spraying air pressure is 60Psi, the auxiliary heating air pressure is 60Psi, the air curtain air pressure is 30Psi, the collision air pressure is 8Psi, and the declustering voltage is 30eV of cetirizine and cetirizine-d 8 respectively; the entrance voltage of the collision chamber is respectively cetirizine and cetirizine-d 8 with 8 eV; cetirizine and cetirizine-d 8 with collision voltage of 25eV respectively; the outlet voltage of the collision chamber is respectively cetirizine and cetirizine-d 8 with 10 eV; detecting in a positive ion mode; the scanning mode is multiple reaction monitoring; the ion reactions for quantitative analysis were: m/z398.1 → m/z201.0, which is cetirizine; and m/z397.2 → m/z201.1, which is cetirizine-d 8.
Preferably, the gradient elution in step (3) is performed by the following procedure:
| total time (min) | Mobile phase A (%) | Mobile phase B (%) |
| 0 | 65 | 35 |
| 1.0 | 65 | 35 |
| 1.1 | 20 | 80 |
| 1.6 | 20 | 80 |
| 1.7 | 65 | 35 |
| 3.5 | 65 | 35 |
Preferably, in the step (2), the concentration of cetirizine in the plasma sample is calculated by adopting an internal standard method and substituting a standard curve equation with the peak area ratio of cetirizine and internal standard cetirizine-d 8.
Preferably, the establishment of the standard curve equation comprises the following steps:
taking 10 parts of 100 mu L blank plasma, placing the blank plasma in a 96-deep-well plate, adding 5 mu L of cetirizine solution with the concentration of 0.02 ng/mu L, 0.1 ng/mu L, 0.2 ng/mu L, 0.4 ng/mu L, 1 ng/mu L, 2 ng/mu L, 4 ng/mu L and 12 ng/mu L to the lowest quantitative limit sample, the standard sample 1, the standard sample 2, the standard sample 3, the standard sample 4, the standard sample 5, the standard sample 6 and the highest quantitative limit sample in the form of stock solution, respectively adding 5 mu L of the cetirizine solution with the volume ratio of 1: 1 to a blank sample and a zero-concentration sample, respectively adding 5 mu L of 0.2 ng/mu L internal standard cetirizine-d 8 solution into the lowest quantitative lower limit sample, the standard 1, the standard 2, the standard 3, the standard 4, the standard 5, the standard 6, the highest quantitative upper limit sample and the zero-concentration sample after uniformly mixing, and adding 5 mu L of the internal standard cetirizine-d 8 solution into the blank sample according to the volume ratio of 1: 1, adding 500 mu L of acetonitrile into 10 samples respectively after uniformly mixing, mixing for 1min by vortex, centrifuging for 10min at 20 ℃ and 3000rpm, taking 50 mu L of supernatant liquid into a 96 deep-well plate filled with 500 mu L of mixed organic solvent, wherein the mixed organic solvent is water: acetonitrile: formic acid according to a volume ratio of 65: 35: 0.1, mixing the obtained mixture, uniformly mixing the mixture by vortex, centrifuging the mixture at the temperature of 20 ℃ at 3000rpm for 5min, and taking the mixture as 10 parts of standard sample to be detected;
and respectively injecting 10 mu L of standard sample into a high performance liquid chromatography-tandem mass spectrometer, detecting chromatographic peaks of the cetirizine in the sample and internal standard cetirizine-d 8, and obtaining a standard curve according to the chromatographic peaks so as to calculate the concentration of the cetirizine in the plasma.
Compared with the prior art, the invention has the following advantages:
(1) the pretreatment method is simple and convenient, two-step organic solution extraction is adopted, and the method is suitable for conventional determination;
(2) the specificity is strong: under the chromatographic conditions adopted in the experiment, the retention time of cetirizine is about 0.863min, and the retention time of internal standard cetirizine-d 8 is about 0.846 min. The cetirizine and the internal standard cetirizine-d 8 have good peak shapes, no interference of miscellaneous peaks in measurement and stable base line;
(3) the sensitivity is high: the minimum limit of quantification of the plasma is 1ng/mL, the concentration of the cetirizine in the plasma can be accurately determined, the sensitivity is high, and the specificity is strong;
(4) the method is rapid, accurate, high in sensitivity and simple and convenient to operate, and provides a basis for determining the blood concentration of cetirizine. The linear range of the plasma standard curve of the method is 1-600 ng/mL, and the precision RSD in batch and between batches is less than +/-15%.
Drawings
FIG. 1 is a standard graph of cetirizine in human plasma as measured by HPLC-MS/MS;
FIG. 2 is a HPLC-MS/MS graph of human blank plasma;
FIG. 3 is a HPLC-MS/MS plot of human blank plasma with added cetirizine and cetirizine-d 8;
FIG. 4 is a HPLC-MS/MS plot of plasma samples with the addition of internal standard cetirizine-d 8 following oral administration of cetirizine or a pharmaceutically acceptable salt thereof to healthy subjects.
Detailed Description
The present invention will be described in further detail with reference to examples.
Example (b): human K2Determination of cetirizine concentration in EDTA plasma
First, experimental material and analytical equipment
Cetirizine (analyte): chinese food & drug certification institute or same, higher grade standard cetirizine-d 8 (internal standard): TLC Pharmaceutical Standards or equivalent, higher-grade Standards
The reagents used are shown in table 1 below:
TABLE 1 details of reagents
| Name of reagent | Rank of | Manufacturer(s) |
| Acetonitrile | HPLC | J.T.Baker |
| Methanol | HPLC | J.T.Baker |
| Formic acid | ACS | Adamas |
Note: the same or higher level of reagents may also be used
The analytical equipment used is shown in table 2 below:
TABLE 2 details of the devices used
| Assembly | Species of | Manufacturer(s) |
| Binary pump (Binary pump) | AC Pump | AB SCIEX |
| Degasser (deaerator) | Degasser | AB SCIEX |
| Column oven (constant temperature Column box) | AC Column oven | AB SCIEX |
| Autosampler (automatic sampler) | AC Autosampler | AB SCIEX |
| Sample rack | Rack Changer | AB SCIEX |
| Mass spectrometer | TRIPLE QUADTM6500+ | AB SCIEX |
| Data processor | Analyst 1.6.3(software) | AB SCIEX |
The same LC/MS system may also be used.
Second, liquid condition
1. Conditions of liquid chromatography
A chromatographic column: agilent ZORBAX XDB-C18, 5 μm, column specification 50X 2.1 mm; temperature of the chromatographic column: 40 ℃; mobile phase A: the volume ratio of water to formic acid is 100/0.1; mobile phase B: the volume ratio of acetonitrile/formic acid is 100/0.1; washing liquid: the volume ratio of methanol to water is 50/50; the autosampler temperature was 15 ℃; gradient elution, flow rate of 0.4mL/min, sample size of 10 μ L, analysis time of 3.5 min.
TABLE 3 gradient elution procedure
| Step (ii) of | Total time (min) | Mobile phase A (%) | Mobile phase B (%) |
| 1 | 0 | 65 | 35 |
| 2 | 1.0 | 65 | 35 |
| 3 | 1.1 | 20 | 80 |
| 4 | 1.6 | 20 | 80 |
| 5 | 1.7 | 65 | 35 |
| 6 | 3.5 | 65 | 35 |
2. Conditions of Mass Spectrometry
The ion source is an electrospray ion source, the spraying voltage is 5000V, the atomizing temperature is 500 ℃, the spraying air pressure is 60Psi, the auxiliary heating air pressure is 60Psi, the air curtain air pressure is 30Psi, the collision air pressure is 8Psi, and the declustering voltage is 30eV of cetirizine and cetirizine-d 8 respectively; the entrance voltage of the collision chamber is respectively cetirizine and cetirizine-d 8 with 8 eV; cetirizine and cetirizine-d 8 with collision voltage of 25eV respectively; the outlet voltage of the collision chamber is respectively cetirizine and cetirizine-d 8 with 10 eV; detecting in a positive ion mode; the scanning mode is multiple reaction monitoring; the ion reactions for quantitative analysis were: m/z398.1 → m/z201.0, which is cetirizine; and m/z397.2 → m/z201.1, which is cetirizine-d 8.
Third, the experimental process
1. Preparation of cetirizine standard solution
Preparing a cetirizine standard solution: cetirizine (analyte) 0.001g is precisely weighed, placed in a 10mL volumetric flask, added with a 1: dissolving the methanol aqueous solution of 1, fixing the volume to scale, shaking up to obtain 100 ng/mu L cetirizine stock solution, and then mixing the solution according to the volume ratio of 1: 1, sequentially diluting the methanol aqueous solution to prepare a cetirizine standard solution, wherein the specific dilution concentration is shown in the following table 4:
TABLE 4 cetirizine standard solution preparation concentration
a: prepared directly from cetirizine (analyte)
The cetirizine standard solution is stored in a plastic container and a refrigerator (4 ℃) when not used, and the volume can be increased or reduced according to the proportion as required.
2. Preparation of standard solution of cetirizine-d 8 internal standard
Preparation of standard solution of cetirizine-d 8 internal standard: 0.001g of cetirizine-d 8 (internal standard) is precisely weighed, placed in a 10mL volumetric flask, and added with a volume ratio of 1: 1, dissolving the methanol aqueous solution, fixing the volume to a scale, shaking up to obtain 100 ng/mu L cetirizine-d 8 stock solution, and then mixing the solution according to the volume ratio of 1: 1, diluting the methanol aqueous solution to prepare a 0.2 ng/. mu.L internal standard solution of cetirizine-d 8, wherein the specific dilution concentration is shown in the following table 5:
TABLE 5 cetirizine-d 8 Standard solution preparation concentration
| Source solution (ng/. mu.L) | Volume of source solution (μ L) | Final volume (mL) | Final concentration (ng/. mu.L) |
| 100a | 200 | 100 | 0.2b |
a: prepared directly from cetirizine-d 8 (internal standard)
b: for sample preparation procedures
The standard solution of cetirizine-d 8 internal standard is stored in plastic containers and refrigerators (4 ℃) when not in use, and the volume can be increased or decreased proportionally according to the needs.
3. Linear test
Putting the blank plasma into a water bath at room temperature for unfreezing; transferring 10 parts of 100 mu L of blank plasma into a 96-deep-well plate (each standard curve sample, blank sample-00 and zero concentration sample-0), respectively and precisely adding 5 mu L of cetirizine standard solution or diluted solution with different concentrations according to the list in the following table 6 to prepare each sample, uniformly mixing to prepare the drug-containing plasma with different concentrations, and carrying out the operation according to 'plasma sample pretreatment'. The ratio Y (Y As/Ai) of the cetirizine peak area As and the internal standard cetirizine-d 8 peak area Ai is calculated, and the peak area ratio Y is used for carrying out regression calculation on the blood concentration X, and the result is shown in a figure 1 and a table 7. And performing regression calculation on the blood concentration X by using the average ratio Y to obtain a regression equation Y of 0.0971X +0.00790 and r of 0.9992. The weight coefficient W is 1/X, and the lowest quantitative limit of the blood concentration of the cetirizine measured by the method is as follows: 1 ng/mL.
TABLE 6 cetirizine Standard Curve formulation concentrations
b: diluted solution of analyte: MeOH/H2O＝50/50
TABLE 7 Standard Curve of cetirizine in human plasma by HPLC-MS/MS method (n ═ 10)
4. Accuracy and precision
Putting the blank plasma into a water bath at room temperature for unfreezing; the appropriate volume of blank plasma was transferred to the appropriate container and cetirizine standard solution was added to prepare 5 drug-containing plasma quality control samples (LLOQ, QL, QLM, QM, QH) of different concentrations and a running standard curve, following the "pretreatment of plasma samples" procedure, the quality control sample preparation was as shown in table 8 below. Making one batch and one following standard curve every day, continuously making 3 days, making 6 samples for each concentration of the first batch and the second batch, making 12 samples for each concentration of the third batch, calculating the ratio Y of the cetirizine peak area As and the internal standard cetirizine-d 8 peak area Ai, substituting the ratio Y into the standard curve on the day to obtain the measured concentration, calculating the precision between batches and the measured concentration according to the measured concentration, and determining the ratio of the measured concentration to the added concentration As the accuracy, wherein the result is shown in Table 9. The result shows that the precision and accuracy of the cetirizine plasma sample in and among batches are less than +/-15 percent and meet the requirements.
TABLE 8 quality control sample preparation concentration
a: final volume is source solution volume + plasma volume
Sufficient volume was dispensed into the labeled sample vials as required for each assay batch and stored at the theoretical temperature-80 ℃. The volume may be scaled up or down as desired.
TABLE 9 determination of Intra-batch, Interbatch precision and accuracy of cetirizine in plasma by HPLC-MS/MS method
5. Interference
Six different blank plasma samples are respectively from different healthy human bodies, and the six different blank plasma samples are prepared and analyzed in the same analysis batch according to the sample preparation steps to evaluate the interference of the different blank plasma on the cetirizine analyte and the internal standard cetirizine-d 8.
After the plasma samples of the blank healthy human from six different sources were prepared and analyzed, the interference peak responses at the retention time of cetirizine were all lower than 20.0% of the cetirizine response of the quantitative lower limit sample in the standard curve of the analysis batch, and the results are shown in table 10. The result shows that the analysis method has specificity on the analysis of cetirizine.
After analysis of the six different source blank healthy human plasma samples, the interference peak responses at retention times consistent with the internal standard were all less than 5.0% of the internal standard response of the quantitative lower limit sample in the standard curve of the analysis lot, see table 11 in the appendix. The results show that the assay is selective for the analysis of internal standards.
TABLE 10 comparison of interference data on cetirizine analyte from blank healthy human plasma from six different sources
a: analyte peak area (selective sample)/analyte peak area (LLOQ of standard curve)
×100.0％≤20.0％
b: the area peak area is considered zero when "no significant peak can be integrated (or no peak)" or "the retention time of the peak area does not match the retention time of the analyte in the sample".
TABLE 11 comparison of interfering data of blank healthy human plasma from six different sources against internal standard cetirizine-d 8
a: analyte peak area (selective sample)/internal standard peak area (LLOQ of standard curve) x 100.0% ≦ 5.0% b: the area peak area is considered zero when "no significant peak can be integrated (or no peak)" or "the retention time of the peak area does not match the retention time of the analyte in the sample".
As can be seen from tables 10 and 11, the blank plasma from different human bodies did not interfere with the cetirizine assay. Therefore, the method can be used for detecting the concentration of cetirizine in the plasma of different human bodies.
6. Human plasma sample detection
(1) Taking human blank plasma without cetirizine administration, precisely adding 100 μ L of blank plasma sample into a 96-deep-well plate, adding 10 μ L of blank plasma sample in a volume ratio of 1: 1, adding 500 mu L of acetonitrile into a 96 deep-hole plate after uniformly mixing, carrying out vortex mixing for 1min, centrifuging for 10min at 20 ℃ at 3000rpm, taking 50 mu L of supernatant liquid into the 96 deep-hole plate filled with 500 mu L of mixed organic solvent, wherein the mixed organic solvent is water: acetonitrile: formic acid according to a volume ratio of 65: 35: 0.1, vortex the resulting mixture, centrifuge at 3000rpm for 5min at 20 ℃ and then take 10. mu.L of sample for LC-MS/MS analysis, the results are shown in FIG. 2.
(2) Precisely adding 100 mu L of blank plasma sample into a 96 deep-well plate without administration of cetirizine, adding 5 mu L of cetirizine standard solution with the concentration of 0.2 ng/mu L, uniformly mixing, adding 5 mu L of 0.2 ng/mu L internal standard cetirizine-d 8 solution, uniformly mixing, adding 500 mu L of acetonitrile into the 96 deep-well plate, carrying out vortex mixing for 1min, centrifuging at 20 ℃ for 10min at 3000rpm, taking 50 mu L of supernatant into the 96 deep-well plate filled with 500 mu L of mixed organic solvent, wherein the mixed organic solvent is water: acetonitrile: formic acid according to a volume ratio of 65: 35: 0.1, vortex the resulting mixture, centrifuge at 3000rpm for 5min at 20 ℃ and then take 10. mu.L of sample for LC-MS/MS analysis, the results are shown in FIG. 3.
(3) Plasma of healthy subjects after oral administration of cetirizine or pharmaceutically acceptable salts thereof is collected, 100 mul of collected human plasma samples are precisely added into a 96-deep-well plate, and 5 mul of plasma samples are added, wherein the volume ratio of the sample to the collected human plasma samples is 1: 1, adding 5 mu L of 0.2 ng/mu L internal standard cetirizine-d 8 solution after uniformly mixing, adding 500 mu L of acetonitrile into a 96 deep-well plate after uniformly mixing, carrying out vortex mixing for 1min, centrifuging for 10min at 20 ℃ at 3000rpm, taking 50 mu L of supernatant into the 96 deep-well plate filled with 500 mu L of mixed organic solvent, wherein the mixed organic solvent is water: acetonitrile: formic acid according to a volume ratio of 65: 35: 0.1, vortex the resulting mixture, centrifuge at 3000rpm for 5min at 20 ℃ and then take 10. mu.L of sample for LC-MS/MS analysis, the results are shown in FIG. 4.
In conclusion, the invention provides a simple and convenient method for determining the concentration of cetirizine in blood plasma by a pretreatment method, adopts a two-step organic solution extraction method, and is suitable for conventional determination; meanwhile, under the chromatographic conditions adopted in the experiment, the retention time of the cetirizine is about 0.863min, the retention time of the internal standard cetirizine-d 8 is about 0.846min, the peak shapes of the cetirizine and the internal standard cetirizine-d 8 are good, the determination of the interference of the miscellaneous peak is avoided, and the base line is stable; the method has high specificity, can accurately determine the concentration of cetirizine in blood plasma, has high sensitivity, and has the minimum limit of blood plasma quantification of 1 ng/mL; meanwhile, the method is rapid, accurate, high in sensitivity and simple and convenient to operate, and provides a basis for determining the blood concentration of cetirizine. The linear range of the plasma standard curve of the method is 1-600 ng/mL, and the precision RSD in batch and between batches is less than +/-15%.
Claims (4)
1. A method for determining the concentration of cetirizine in blood plasma by liquid chromatography-mass spectrometry is characterized in that: the plasma sample is pretreated and then the concentration of the plasma sample is detected by high performance liquid chromatography-tandem mass spectrometry, and the specific method comprises the following steps:
(1) pretreatment of a plasma sample:
plasma with K2EDTA as anticoagulant, cetirizine-d 8 as internal standard; precisely adding 100 μ L of plasma sample into a 96-deep-well plate, adding 5 μ L of plasma sample at a volume ratio of 1: 1, adding 5 mu L of 0.2 ng/mu L internal standard cetirizine-d 8 solution after uniformly mixing, adding 500 mu L of acetonitrile into a 96 deep-well plate after uniformly mixing, carrying out vortex mixing for 1min, centrifuging for 10min at 20 ℃ at 3000rpm, taking 50 mu L of supernatant into the 96 deep-well plate filled with 500 mu L of mixed organic solvent, wherein the mixed organic solvent is water: acetonitrile: formic acid according to a volume ratio of 65: 35: 0.1, mixing the obtained mixture, uniformly mixing the mixture by vortex, centrifuging the mixture at the temperature of 20 ℃ and 3000rpm for 5min, and taking the mixture as a test sample to be detected;
(2) and (3) sample measurement:
injecting 10 mu L of test sample into a high performance liquid chromatography-tandem mass spectrometer, detecting chromatographic peaks of cetirizine and internal standard cetirizine-d 8 in the sample, and calculating the concentration of cetirizine in the plasma sample according to the chromatographic peaks;
(3) liquid chromatography determination, conditions are as follows:
a chromatographic column: agilent ZORBAX XDB-C18, 5 μm, column specification 50X 2.1 mm; temperature of the chromatographic column: 40 ℃; mobile phase A: the volume ratio of water to formic acid is 100/0.1; mobile phase B: the volume ratio of acetonitrile/formic acid is 100/0.1; washing liquid: the volume ratio of methanol to water is 50/50; the autosampler temperature was 15 ℃; gradient elution with flow rate of 0.4mL/min, sample size of 10 μ L, and analysis time of 3.5 min;
(4) mass spectrometry under the conditions:
the ion source is an electrospray ion source, the spraying voltage is 5000V, the atomizing temperature is 500 ℃, the spraying air pressure is 60Psi, the auxiliary heating air pressure is 60Psi, the air curtain air pressure is 30Psi, the collision air pressure is 8Psi, and the declustering voltage is 30eV of cetirizine and cetirizine-d 8 respectively; the entrance voltage of the collision chamber is respectively cetirizine and cetirizine-d 8 with 8 eV; cetirizine and cetirizine-d 8 with collision voltage of 25eV respectively; the outlet voltage of the collision chamber is respectively cetirizine and cetirizine-d 8 with 10 eV; detecting in a positive ion mode; the scanning mode is multiple reaction monitoring;
the ion reactions for quantitative analysis were: m/z398.1 → m/z201.0, which is cetirizine; and m/z397.2 → m/z201.1, which is cetirizine-d 8.
2. The method for determining the concentration of cetirizine in plasma by liquid chromatography-mass spectrometry according to claim 1, wherein: the gradient elution procedure in the step (3) is as follows:
3. the method for determining the concentration of cetirizine in plasma by LC-MS according to claim 1 or 2, wherein: in the step (2), an internal standard method is adopted, and the concentration of the cetirizine in the plasma sample is calculated by substituting the peak area ratio of the cetirizine and the internal standard cetirizine-d 8 into a standard curve equation.
4. The method for determining the concentration of cetirizine in plasma by LC-MS according to claim 3, wherein: the establishment of the standard curve equation comprises the following steps:
taking 10 parts of 100 mu L blank plasma, placing the blank plasma in a 96-deep-well plate, adding 5 mu L of cetirizine solution with the concentration of 0.02 ng/mu L, 0.1 ng/mu L, 0.2 ng/mu L, 0.4 ng/mu L, 1 ng/mu L, 2 ng/mu L, 4 ng/mu L and 12 ng/mu L to the lowest quantitative limit sample, the standard sample 1, the standard sample 2, the standard sample 3, the standard sample 4, the standard sample 5, the standard sample 6 and the highest quantitative limit sample in the form of stock solution, respectively adding 5 mu L of the cetirizine solution with the volume ratio of 1: 1 to a blank sample and a zero-concentration sample, respectively adding 5 mu L of 0.2 ng/mu L internal standard cetirizine-d 8 solution into the lowest quantitative lower limit sample, the standard 1, the standard 2, the standard 3, the standard 4, the standard 5, the standard 6, the highest quantitative upper limit sample and the zero-concentration sample after uniformly mixing, and adding 5 mu L of the internal standard cetirizine-d 8 solution into the blank sample according to the volume ratio of 1: 1, adding 500 mu L of acetonitrile into 10 samples respectively after uniformly mixing, mixing for 1min by vortex, centrifuging for 10min at 20 ℃ and 3000rpm, taking 50 mu L of supernatant liquid into a 96 deep-well plate filled with 500 mu L of mixed organic solvent, wherein the mixed organic solvent is water: acetonitrile: formic acid according to a volume ratio of 65: 35: 0.1, mixing the obtained mixture, uniformly mixing the mixture by vortex, centrifuging the mixture at the temperature of 20 ℃ at 3000rpm for 5min, and taking the mixture as 10 parts of standard sample to be detected;
and respectively injecting 10 mu L of standard sample into a high performance liquid chromatography-tandem mass spectrometer, detecting chromatographic peaks of the cetirizine in the sample and internal standard cetirizine-d 8, and obtaining a standard curve according to the chromatographic peaks so as to calculate the concentration of the cetirizine in the plasma.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911082265.XA CN110927308A (en) | 2019-11-07 | 2019-11-07 | Method for determining concentration of cetirizine in blood plasma by liquid chromatography-mass spectrometry |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911082265.XA CN110927308A (en) | 2019-11-07 | 2019-11-07 | Method for determining concentration of cetirizine in blood plasma by liquid chromatography-mass spectrometry |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110927308A true CN110927308A (en) | 2020-03-27 |
Family
ID=69852561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911082265.XA Withdrawn CN110927308A (en) | 2019-11-07 | 2019-11-07 | Method for determining concentration of cetirizine in blood plasma by liquid chromatography-mass spectrometry |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110927308A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114814018A (en) * | 2022-04-18 | 2022-07-29 | 合肥创新医药技术有限公司 | Method for determining doxylamine in human plasma through LC-MS/MS |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101224203A (en) * | 2007-08-22 | 2008-07-23 | 大连医科大学附属第二医院 | Tanshinone IIA microemulsions and preparing method thereof |
| CN101762645A (en) * | 2008-10-27 | 2010-06-30 | 曹翠珍 | Method for measuring concentration of cetirizine in human urine |
| CN103263394A (en) * | 2013-05-27 | 2013-08-28 | 深圳国源国药有限公司 | Cetirizine hydrochloride tablet and related substance quality control method thereof |
| CN105954419A (en) * | 2016-06-01 | 2016-09-21 | 重庆华邦胜凯制药有限公司 | Method for separating and determining levocetirizine hydrochloride and enantiomer thereof through HPLC method |
| CN107328871A (en) * | 2017-05-12 | 2017-11-07 | 中国医学科学院肿瘤医院 | Ao Xi replaces the drug concentration of Buddhist nun in UPLC MS/MS combinations detection human plasma and/or cerebrospinal fluid |
-
2019
- 2019-11-07 CN CN201911082265.XA patent/CN110927308A/en not_active Withdrawn
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101224203A (en) * | 2007-08-22 | 2008-07-23 | 大连医科大学附属第二医院 | Tanshinone IIA microemulsions and preparing method thereof |
| CN101762645A (en) * | 2008-10-27 | 2010-06-30 | 曹翠珍 | Method for measuring concentration of cetirizine in human urine |
| CN103263394A (en) * | 2013-05-27 | 2013-08-28 | 深圳国源国药有限公司 | Cetirizine hydrochloride tablet and related substance quality control method thereof |
| CN105954419A (en) * | 2016-06-01 | 2016-09-21 | 重庆华邦胜凯制药有限公司 | Method for separating and determining levocetirizine hydrochloride and enantiomer thereof through HPLC method |
| CN107328871A (en) * | 2017-05-12 | 2017-11-07 | 中国医学科学院肿瘤医院 | Ao Xi replaces the drug concentration of Buddhist nun in UPLC MS/MS combinations detection human plasma and/or cerebrospinal fluid |
Non-Patent Citations (6)
| Title |
|---|
| 任进民 等: "LC-MS/MS法测定人血浆中西替利嗪的浓度", 《中国药房》 * |
| 刘美玲 等: "LC-MS/MS法测定Beagl犬血浆中ET-26盐酸盐及其代谢产物ET-acid", 《中国测试》 * |
| 徐珊珊 等: "液相色谱-串联质谱法同时测定人血浆中西替利嗪和伪麻黄碱的浓度", 《中国临床药学杂志》 * |
| 梅升辉 等: "LC-MS/MS法测定人血浆中卡马西平的浓度及其在室间质评中的应用", 《中国药房》 * |
| 赵慧人 等: "西替利嗪伪麻黄碱缓释胶囊中的伪麻黄碱的人体药物动力学研究", 《中南药学》 * |
| 邹敏 等: "国产盐酸西替利嗪咀嚼片人体药动学研究", 《海峡药学》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114814018A (en) * | 2022-04-18 | 2022-07-29 | 合肥创新医药技术有限公司 | Method for determining doxylamine in human plasma through LC-MS/MS |
| CN114814018B (en) * | 2022-04-18 | 2024-05-24 | 合肥创新医药技术有限公司 | Method for determining doxylamine in human plasma by LC-MS/MS |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111175394B (en) | Method for detecting plasma catecholamine and metabolite thereof by liquid chromatography-tandem mass spectrometry | |
| CN113933423B (en) | Detection method for determining 23 kinds of psychotropic drugs and metabolites in human serum | |
| CN108918722B (en) | Method for detecting NMDA receptor antagonist JCC-02 blood concentration based on HPLC-MS/MS technology | |
| CN110927307A (en) | Method for determining concentration of tadalafil in blood plasma by liquid chromatography-mass spectrometry | |
| CN112834657A (en) | Method for determining concentration of amlodipine in blood plasma by liquid chromatography-mass spectrometry | |
| CN111458440A (en) | Method for detecting free ezetimibe and total ezetimibe in plasma by liquid chromatography-tandem quadrupole mass spectrometry | |
| CN110927308A (en) | Method for determining concentration of cetirizine in blood plasma by liquid chromatography-mass spectrometry | |
| CN112782323A (en) | Method for determining concentration of omeprazole in blood plasma by liquid chromatography-mass spectrometry | |
| CN112630352A (en) | Method for determining concentration of lacosamide in blood plasma by liquid chromatography-mass spectrometry | |
| CN109142593A (en) | HPLC-DAD method measures Quetiapine drug concentration in human serum | |
| CN114544796B (en) | Method for measuring settop alcohol in plasma by liquid phase mass spectrometry | |
| CN112748205A (en) | Method for determining terazosin concentration in blood plasma by liquid chromatography-mass spectrometry | |
| CN112763619A (en) | Method for determining concentration of fludrocortisone in blood plasma by liquid chromatography-mass spectrometry | |
| CN110927304A (en) | Method for determining concentration of glimepiride in plasma by liquid chromatography-mass spectrometry | |
| CN110927306A (en) | Method for determining concentration of ibuprofen in blood plasma by liquid chromatography-mass spectrometry | |
| CN113933418A (en) | Method for simultaneously detecting concentrations of 7 antibiotic drugs in human serum | |
| CN112461961A (en) | Method for determining concentration of mizolastine in human plasma | |
| CN113866315A (en) | Quantitative analysis method for detecting rat plasma YG-18 blood concentration by liquid chromatography-mass spectrometry technology | |
| CN110927305A (en) | Method for determining glipizide concentration in plasma by liquid chromatography-mass spectrometry | |
| CN113109493A (en) | Method for measuring rifampicin in plasma by high performance liquid chromatography-mass spectrometry | |
| CN115078621B (en) | Method for measuring concentration of irinotecan derivative Dxd in blood plasma | |
| CN111044658A (en) | Method for determining concentration of ambroxol in blood plasma by liquid chromatography-mass spectrometry | |
| CN112903888A (en) | Method for determining concentration of valsartan in blood plasma by liquid chromatography-mass spectrometry | |
| CN115267037B (en) | Method for measuring concentration of SHP099 in plasma | |
| CN111044661A (en) | Method for determining concentration of montelukast in blood plasma by liquid chromatography-mass spectrometry |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20200327 |